Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors

Shiratori, Souichi; Sugita, Junichi; Fuji, Shigeo et al.

Bone marrow transplantation, 2021, 56, 2231-2240

Permalink : https://hdl.handle.net/2115/83238

このアイテムのアクセス数:997件（2026-08-08 06:36 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
23817_2_merged_1618278869 pdf 478 KB 776 Main text
23817_2_supp_365000_qqk78f_convrt pdf 917 KB 287 Supplemental material

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/83238
タイトル
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors
著者
Shiratori, Souichi ; Sugita, Junichi ; Fuji, Shigeo ; Aoki, Jun ; Sawa, Masashi ; Ozawa, Yukiyasu ; Hashimoto, Daigo ; Matsuoka, Ken-ichi ; Imada, Kazunori ; Doki, Noriko ; Ashida, Takashi ; Ueda, Yasunori ; Tanaka, Masatsugu ; Sawayama, Yasushi ; Ichinohe, Tatsuo ; Terakura, Seitaro ; Morishima, Satoko ; Atsuta, Yoshiko ; Fukuda, Takahiro ; Teshima, Takanori
e-Rad_Researcher
00645905
著者名
Shiratori, Souichi
著者名
Sugita, Junichi
著者名
Fuji, Shigeo
著者名
Aoki, Jun
著者名
Sawa, Masashi
著者名
Ozawa, Yukiyasu
著者名
Hashimoto, Daigo
著者名
Matsuoka, Ken-ichi
著者名
Imada, Kazunori
著者名
Doki, Noriko
著者名
Ashida, Takashi
著者名
Ueda, Yasunori
著者名
Tanaka, Masatsugu
著者名
Sawayama, Yasushi
著者名
Ichinohe, Tatsuo
著者名
Terakura, Seitaro
著者名
Morishima, Satoko
著者名
Atsuta, Yoshiko
著者名
Fukuda, Takahiro
e-Rad_Researcher
40284096
著者名
Teshima, Takanori
言語
英語
発行日
2021-09
出版者
Springer Nature
収録物名
Bone marrow transplantation
巻(号)
56
ページ
2231-2240
抄録
Antithymocyte globulin (ATG) has been shown to reduce chronic graft-versus-host disease (GVHD) particularly in allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated donors; however, anti-GVHD effects of lower doses of ATG remains to be elucidated. We conducted a nationwide retrospective study to compare the outcomes of unrelated PBSCT with or without rabbit ATG (thymoglobulin) in 287 patients. A median ATG dose was 2.0 mg/kg. The primary endpoint, the cumulative incidence of moderate-severe chronic GVHD at 2 years was 22.1% in the ATG group, which was significantly less than that in the non-ATG group (36.3%, P = 0.025). The ATG group had a higher incidence of immunosuppressant discontinuation, GVHD-free, relapse-free survival, and moderate-severe chronic GVHD-free, relapse-free survival at 2 years compared to the non-ATG group. The incidences of grade III-IV aGVHD and moderate-severe chronic GVHD were significantly higher in patients with high absolute lymphocyte count (ALC) before the administration of ATG, whereas relapse rate was significantly higher in patients with low ALC before ATG. In conclusion, low-dose ATG effectively suppresses chronic GVHD in unrelated PBSCT, and ALC before ATG may be a potential predictor for GVHD and relapse.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
PISSN
0268-3369
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1038/s41409-021-01314-w